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The relationship between mucosal
inflammatory cells, specific
symptoms, and psychological
functioning in youth with irritable
bowel syndrome
Meenal Singh1, Vivekanand Singh2, Jennifer V. Schurman1, Jennifer M. Colombo1 &
Craig A. Friesen1*
Both mucosal inflammation and psychologic dysfunction have been implicated in irritable bowel
syndrome (IBS). While some relationships between inflammation (mast cells and eosinophils)
and depression have been reported in adults with IBS, relationships between inflammation and
psychologic function have not been studied in children and adolescents. The aims of the current
study were to: (1) assess densities of colonic mast cells, eosinophils, and TH17 cells in youth with
IBS; and, (2) explore relationships between these cells and specific IBS symptoms and psychologic
functioning. Utilizing previously obtained biopsies from the descending and rectosigmoid colons,
densities were determined for mast cells, eosinophils, and TH17 cells, respectively, in 37 youth with
IBS and 10 controls. In IBS patients, densities were assessed in relation to specific IBS symptoms and
in relation to self-report anxiety and depression scores. In both the descending and rectosigmoid
colons, densities of mast cells, eosinophils, and TH17 cells were higher in IBS patients as compared to
controls. In IBS patients, rectosigmoid mast cell density was higher in those reporting pain relief with
defecation. Also, in IBS patients, rectosigmoid eosinophilia was associated with higher anxiety scores
and eosinophil density correlated with depression scores. In the descending colon, eosinophil and
mast cell densities both correlated with depression scores. In conclusion, mucosal inflammation (mast
cells and eosinophils) is associated with pain relief with defecation and with anxiety and depression in
youth with IBS.
Chronic or recurrent abdominal pain affects a substantial proportion of children and adolescents1,2. The majority of youth with chronic abdominal pain will not have an identified organic disease but will report symptoms
consistent with one of the functional gastrointestinal disorders (FGIDs) as defined by Rome c riteria3,4. There are
four pain related FGIDs with irritable bowel syndrome (IBS) being one of the two most c ommon5. Rome IV, the
most current version of Rome criteria, defines IBS by the presence of one of the following symptoms: pain related
to defecation, pain associated with a change in stool frequency, or pain associated with a change in stool form4.
IBS is further sub-categorized as IBS with predominant constipation (IBS-C), IBS with predominant diarrhea
(IBS-D), mixed IBS with alternating constipation and diarrhea (IBS-M), and as unsubtyped4,6. Among a variety
of other factors, visceral hyperalgesia, inflammation and psychosocial factors have been highly implicated in
the pathogenesis of IBS7,8.
Inflammatory cells which have been evaluated in IBS include mast cells, eosinophils, and lymphocytes,
particularly T cells. Mast cells have been highly implicated in IBS pathogenesis in both IBS-C and IBS-D9,10. IBS
has been associated with an increase in the density of degranulating mast cells, while the density of mast cells in
close proximity to enteric nerves correlates with abdominal pain s everity11.
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Location

Cell type

IBS patients

Controls

Rectosigmoid

Eosinophils

19.0 ± 11.4

10.1 ± 6.0

P value
0.022

Rectosigmoid

Mast cells

19.8 ± 6.4

10.7 ± 6.3

< 0.001

Rectosigmoid

TH17 cells

1.2 ± 0.5

0.5 ± 0.5

0.001

Descending

Eosinophils

26.8 ± 15.1

15.2 ± 4.0

< 0.001

Descending

Mast cells

21.5 ± 8.0

8.7 ± 2.9

< 0.001

Descending

TH17 cells

1.2 ± 0.6

0.4 ± 0.5

0.001

Table 1.  Mean mucosal peak eosinophil, mast cell, and TH17 densities in the rectosigmoid and descending
colons of youth with IBS patients (n = 37) and controls (n = 10).

Eosinophils have been much less studied in the context of IBS. Although one study reported increased cecal
eosinophils in adults with IBS, most studies, including one pediatric study, have found no differences in eosinophil density or in stool eosinophil protein c oncentrations12–18. While eosinophils do not appear to be increased
across the population of patients with IBS, there may be a subset where eosinophils play a role. Park and colleagues reported increased colonic eosinophils in a subset (23 out of 42) of IBS p
 atients19.
T lymphocytes have been implicated in both adult and pediatric IBS but TH17 cell density has not been
specifically evaluated8,20. IL-17 has been implicated in IBS, particularly post-infectious IBS, in some but not all
studies21–23. Increased serum IL-17 has been associated with D-IBS and related to symptom severity in one study,
while serum IL-17 did not differ between IBS patients and controls in another s tudy24,25. To our knowledge,
density of mucosal TH17 cells has not previously been evaluated in IBS.
IBS is associated with high rates of anxiety and depression in adults which may be associated with visceral
hyperalgesia and autonomic nervous system dysfunction26. In children with IBS, anxiety and depression correlate
with abdominal pain severity27. In adults with IBS, mast cells density has been associated with depression12,28. To
our knowledge, relationships between mucosal mast cells and psychological functioning have not been evaluated
in children with IBS, but we have previously found an association between antral mast cells and both anxiety and
depression in children with functional dyspepsia, which is another pain-associated F
 GID29. A recent study of
adults with IBS in the general population found an association between eosinophil density in the transverse and
sigmoid colon with depressive s ymptoms30. These studies suggest an association between colonic inflammation
and psychologic functioning, at least in adults.
The goal of the current exploratory study was to further assess relationships between inflammation, symptoms, and psychologic functioning in youth with IBS which would have the potential to alter current treatment
models. The aims were to: (1) assess densities of colonic mast cells, eosinophils, and TH17 cells in children and
adolescents with IBS; and, (2) explore relationships between these cells and specific IBS symptoms and psychologic functioning.

Results

Participants. IBS patients (N = 37) ranged in age from 8 to 17 years (mean 13.8 ± 2.2 years). Seventy percent
were female. All patients fulfilled Rome IV criteria for IBS. IBS subtypes consisted of IBS-D in 45.9%, IBS-M
in 24.3%, IBS-C in 16.2%, and unsubtyped in 13.5%. Stools were reported to be less than daily by 13.5%, daily
by 32.4%, twice daily by 27%, and three times or more daily by 27% of patients. A change in stool frequency
was reported by 59.5%, a change in stool form by 67.6%, and pain relief with defecation by 51.4%. Twenty-four
patients reported at least 2 of these symptoms. Of the 13 patients reporting only one symptom, pain relief with
defecation was reported by 54%, a change in stool form by 31%, and a change in stool frequency by 15%.
Cell densities. Peak eosinophil density ranged from 5 to 62 in the rectosigmoid and 9 to 71 in the descend-

ing colon of IBS patients, and from 4 to 23 in the rectosigmoid and 9 to 22 in the descending colon of controls.
Peak mast cell density ranged from 8 to 34 in the rectosigmoid and from 11 to 51 in the descending colon of
IBS patients, and from 5 to 27 in the rectosigmoid and 6 to 14 in the descending colon of controls. Peak TH17
density ranged from 0 to 3 in the rectosigmoid and from 0 to 4 in the descending colon of IBS patients, and from
0 to 1 in the rectosigmoid and 0 to 1 in the descending colon of controls. In both locations, peak TH17 densities
were 1 or less in 83.8% of IBS patients. For ease of interpretation, mean cell densities in IBS patients and controls
are shown in Table 1 along with p values as determined by Mann Whitney U. While all statistical tests were
significant between the two groups, given the lack of variability and the relative paucity of TH17 cells, they were
excluded from further analysis. The distribution for cell counts is shown in Fig. 1.

Cell densities and specific symptoms.

For IBS patients reporting relief of pain with defecation as compared to those reporting no relief, peak rectosigmoid mast cell density was increased while eosinophil densities
did not differ. (Table 2) Neither eosinophil nor mast cell densities differed between IBS patients reporting and
those not reporting a change in stool frequency, a change in stool form, diarrhea, or constipation, respectively.
Likewise, cell densities did not differ between patients with IBS-C, IBS-D, IBS-M, and unsubtyped IBS.

Cell densities and psychologic function. Complete BASCs were available from 35 patients (95%). Anxiety scores ranged from 38 to 78 (mean 56.4 ± 11.3). Anxiety scores were < 60 in 63%, 60–69 in 23%, and ≥ 70 in
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Figure 1.  Distribution of mucosal peak eosinophils and mast cells by location for youth with IBS (n = 37) and
controls (n = 10). Raw cell count data is pictured for all individuals in each study group. (A) Rectosigmoid peak
eosinophils. (B) Rectosigmoid peak mast cells. (C) Descending colon peak eosinophils. (D) Descending colon
peak mast cells. Peak cell counts significantly higher across location for youth with IBS versus controls (see
Table 1 for p values).
Location

Cell type

Pain relieved

Pain not relieved

P value

Rectosigmoid

Eosinophils

16.4 ± 8.3

21.7 ± 13.6

0.159

Rectosigmoid

Mast cells

22.3 ± 6.2

17.1 ± 5.7

0.011

Descending

Eosinophils

24.1 ± 12.7

29.7 ± 17.2

0.265

Descending

Mast cells

22.1 ± 6.8

20.8 ± 9.3

0.636

Table 2.  Mean mucosal peak eosinophil and mast cell densities in the rectosigmoid and descending colons of
youth with IBS patients reporting pain relief with defecation (n = 19) vs. those reporting no pain relief (n = 18).

14%. Depression scores ranged from 40 to 86 (mean 50.97 ± 11.3). Depression scores were < 60 in 83%, 60–69
in 9%, and ≥ 70 in 9%. We assessed relationships utilizing clinical cut-offs for eosinophil density as these would
have the potential to map onto treatment. In addition, because there is not universal agreement on density cutoffs, we assessed correlations between cell densities and psychological scores. Rectosigmoid peak eosinophils
≥ 10/hpf were associated with higher self-report anxiety (57.62 vs. 50.33; p = 0.032; Cohen’s d = 0.792). Rectosigmoid peak eosinophils ≥ 10/hpf were not associated with higher self-report depression scores (52.2 ± 12.0 vs.
44.8 ± 3.3; p = 0.147; Cohen’s d = 0.843). Peak rectosigmoid eosinophil density was correlated with self-report
depression (r = 0.346; p = 0.04) Descending colon peak eosinophils ≥ 25/hpf were associated with higher selfreport depression (62.7 vs. 54.7; p = 0.047; Cohen’s d = 0.690). Peak descending colon eosinophil density was
correlated with self-report depression (r = 0.344; p = 0.04). Peak rectosigmoid mast cells density did not correlate
with either self-report anxiety or depression scores. Peak descending colon mast cell density correlated with
depression scores (r = 0.344; p = 0.04) but not anxiety scores.
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Discussion

The current study further supports a role for mast cells and possibly for eosinophils in youth with IBS. Although
their density was increased over controls, TH17 cells were sparse casting doubt on any significant pathogenic
role in IBS. Relationships were demonstrated in this group of patients with “pure” IBS; it is unknown whether
these relationships would hold true for patients with IBS who also have overlapping FD.
Mast cells have been highly implicated in IBS where mast cells are generally increased in density, are in closer
proximity to nerves, and are more likely to be degranulated9–11,14,31. In the current study, we also found increased
mast cell density in the descending and rectosigmoid colon. Mast cell density was higher in IBS patients reporting
relief of pain with defecation as compared to those not experiencing relief. Mast cell density did not differ between
IBS patients who did and did not report pain associated with a change in stool form or frequency, diarrhea, or
constipation. This differential association with cardinal IBS symptoms is perhaps not surprising as two previous
pediatric factor analyses have not supported inclusion of pain relief with defecation in the IBS symptom complex
in children and a dolescents32,33. It is possible that symptoms may be less associated with symptom complexes
and more with site-specific mast cell density. It is also possible that the lack of association with stool form and
frequency is because both are under the influence of a number of other factors independent of inflammatory cells
which were uncontrolled, especially diet. The mechanism accounting for pain relief with stooling is not clear but
it might be explained by visceral hyperalgesia, as IBS has been associated with rectal sensitivity to distension in
both adults and c hildren34,35. In an animal model, visceral hyperalgesia is preceded by infiltration with mast cells
and eosinophils36. Mast cells release mediators, primarily histamine and proteases, which can induce visceral
hyperalgesia through upregulation of TRP channels, substance P, and NGF37–39. Mast cell-nerve interactions are
directly related to pain frequency and severity in both children and a dults11,40. There is some evidence that mast
cell stabilization may decrease visceral sensitivity in adults with visceral h
 yperalgesia41.
In the current study, in addition to the increase in mast cells, eosinophil density was also increased in the
descending and rectosigmoid colon of IBS patients. In adults, there has been conflicting findings related to
eosinophil density in I BS9. Park and colleagues reported that while overall, eosinophils were not increased
in IBS, there may be a subset of patients with e osinophilia19. De Silva and colleagues reported an increase in
eosinophils in IBS but only in the c ecum13. Previously, eosinophils have been largely unstudied in pediatric IBS
except for one study where no eosinophils were seen in IBS patients or controls15. This is a challenging area of
inquiry as true asymptomatic control data is not available because it is unethical to perform invasive procedures
on children without symptoms. In presumptive normal controls, there is a wide range of “normal” eosinophil
densities42. Given the interactions between mast cells and eosinophils, it is certainly plausible that eosinophils
would be increased with mast cell activation43–45. We did not collect data on food allergies but is possible that the
patients with eosinophilia might be ones with atypical food reactions. For example, self-reported wheat intolerance is associated with IBS and non-celiac wheat sensitivity is associated with increased duodenal and rectal
eosinophils46,47. Utilizing provocative duodenal mucosal food challenges, atypical food allergies were identified in
70% of IBS patients with wheat accounting for 61% of t hese48. Positive reactions were associated with eosinophil
degranulation without increased eosinophil d
 ensity48.
We found significant relationships between mast cells and eosinophils, respectively, with psychological functioning. Increased mast cells in the descending colon were associated with increased depression scores. This is
consistent with the relationship previously reported in adults with IBS12,28. It is also consistent with previous
findings in children with functional dyspepsia where increased mast cells in the antrum were associated with
increased anxiety and depression29. In the current study, elevated rectal eosinophils were associated with higher
anxiety. While they were not significantly associated with depression, this may have been the result of a small
sample size given the large effect size and that rectosigmoid eosinophil density was positively correlated with
depression. Elevated descending colon eosinophils were associated with depression. These findings are consistent
with a recent report in adults with IBS showing an association between colonic eosinophils and d
 epression30.
In summary, the current study indicates a relationship between mast cells and eosinophils with anxiety and/
or depression. This association does not indicate cause-and-effect but raises the possibility that psychologic
dysfunction may lead to inflammation or that mediators released from mast cells and eosinophils may induce
anxiety and/or depression.
The current study has some limitations which should be noted. It is a relatively small sample size largely
because we excluded patients with any symptoms consistent with dyspepsia and particularly under Rome IV
criteria, there is a significant overlap between IBS and functional dyspepsia5. Given the cross-sectional design
of the study, we were only able to demonstrate associations but not a cause-and-effect relationship between
inflammatory cells and psychologic dysfunction. It should also be noted that cell densities are a gross measure
of inflammation and may not be indicative of cell activation with subsequent release of mediators which may
be of key importance in interactions between inflammation and specific symptoms or psychologic functioning.
In conclusion, we found an increase in mast cells and eosinophils in the rectosigmoid and descending colons
of youth with IBS. Increases in rectosigmoid mast cells were associated with reports of pain improving with defecation, possibly suggesting a role in visceral sensitivity to distension. Mast cells and eosinophils were associated
with anxiety and depression. Future studies should assess specific mediators which may explain interactions with
peripheral or central neuronal function and whether visceral sensitivity or psychologic functioning are amenable
to medications directed at specific mediators or mast cell stabilization.

Methods

Participants. The study was approved by the Institutional Review Board (IRB) Children’s Mercy Kansas
City and performed in accordance with the Declaration of Helsinki. Informed consent/assent was waived by the
IRB for this retrospective study. We utilized a convenience sample, retrospectively screening 250 consecutive
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patients presenting to an abdominal pain clinic. We identified 37 patients who had undergone colonoscopy and
who were diagnosed with irritable bowel syndrome (IBS) without overlapping functional dyspepsia utilizing
Rome IV criteria. We excluded patients with overlapping FD as FD has previously been shown to exhibit relationships between inflammation, symptoms, and psychologic function29. All patients were diagnosed by a single
board-certified pediatric gastroenterologist in an abdominal pain clinic at Children’s Mercy Kansas City. All 37
patients had undergone colonoscopy with a normal gross examination. A minimum of 2 biopsies were obtained
from the descending colon and the rectosigmoid colon. All patients were negative for nodularity, erosions, and
ulcers. Patients ranged in age from 8 to 17 years and reported abdominal pain which occurred at least weekly
for a minimum of 8 weeks.
Control specimens from 10 children (age 8–17 years) were identified from a pathology database and included
patients who underwent colonoscopy for hematochezia. All had normal gross colonoscopies with the exception
that they were not excluded for a single non-adenomatous polyp, fissures, or skin tags. All had biopsies with a
pathology report of no diagnostic abnormality. All denied a history of abdominal pain, constipation, or diarrhea. We did not sex or age-match controls as colonic cell density does not appear to be affected by sex or age
in children49–51.

Measures. Questionnaires. As part of routine clinical care, all patients with IBS completed a standard medical questionnaire that contained specific questions regarding symptoms required to classify patients according
to Rome IV criteria, as well as other gastrointestinal symptoms including diarrhea and constipation. IBS patients
also completed the Behavior Assessment System for Children—Second Edition (BASC-2) to assess for symptoms of anxiety and depression as part of routine clinical e valuation52. The BASC-2 has demonstrated criterionrelated and construct validity, has good internal consistency for most individual subscales, and is widely used in
both clinical and research settings52. Standardized T scores for the self-report depression and anxiety subscales
were used for the current study. A score of 60–70 is considered at clinical risk while a score ≥ 70 is considered
clinically meaningful.
Histologic Evaluation. The previously obtained biopsy specimens were utilized to assess eosinophil, mast cell,
and TH17 cell densities, respectively, in both the descending colon and the rectosigmoid colon. All assessments
were performed by a single observer (MS) blinded to group assignment and clinical history. Hematoxylin and
eosin (H&E) stained slides obtained from these patients as part of routine care were used to assess eosinophil
density. Immunohistochemical (IHC) staining for tryptase and CCR6 was performed manually on formalinfixed, paraffin-embedded tissue sections to identify mast cells and TH17 cells, respectively. Anti-human mast
cell tryptase (Dako; clone AA1) was used to identify mast cells. CCR6 IHC staining (Novus Biologicals; clone
18B9E6), was used to identify TH17 cells.
To determine eosinophil density, hematoxylin and eosin stained sections were initially scanned at 10 × objective magnification to determine subjective areas of maximal density. Selecting areas of maximal density has been
utilized to assess eosinophil density in children as involvement is often uneven47,53. Eosinophils were counted
in five consecutive high-power fields (hpf; 40 × objective magnification). Likewise, mast cells tryptase-positive
cells) and TH17 cells (CCR6-positive cells) were counted in five consecutive hpf after determining subjective
areas of maximal involvement. All cell types were counted only in the lamina propria of the mucosa. Peak cell
densities were determined in both the descending and rectosigmoid colons. All cell counts were performed by
a single observer (MS).
Statistical analysis. For each continuous variable, normality was assessed utilizing the Kolmogorov–
Smirnov statistic. Continuous variables (e.g. cell densities and BASC scores) were compared between groups utilizing the Student’s t test when the distribution was normal and the Mann–Whitney U when the distribution was
non-normal. One-way ANOVA was utilized for multiple group comparisons. Given the exploratory nature of
this study and that we believed that the results of individual tests were important, we did not adjust for multiple
comparisons as we were more concerned with Type II errors. Alternatively, we reported effect sizes where appropriate as has been recommended, calculating the cohen’s d
 54,55. Pearson correlations were assessed for eosinophil
and mast cell densities, respectively, with BASC scores. A p value less than 0.05 was considered significant.
Received: 6 March 2020; Accepted: 29 June 2020
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